Peptides and Post-Herpetic Neuralgia: Nerve Pain After Shingles

By the NorthPeptide Research Team — Updated January 2026

What Is Post-Herpetic Neuralgia?

Post-herpetic neuralgia is a complication of shingles (herpes zoster), caused by the varicella-zoster virus reactivating along nerve pathways. After the rash clears, the virus can leave behind lasting nerve damage. Pain described as burning, stabbing, or electric-shock-like can persist for months or years. Standard care includes anticonvulsants, antidepressants, topical lidocaine, and opioids — but many patients find limited relief. This is why researchers have turned to peptide compounds as potential adjunct tools.

Why Peptides May Be Relevant to PHN Research

PHN is fundamentally a nerve-damage problem. The varicella-zoster virus inflames and scars the dorsal root ganglia — clusters of sensory neurons. The resulting sensitization of pain pathways is what makes PHN so difficult to treat. Peptides being studied in this context generally work in one of three ways:

• Neuroregeneration: Promoting growth and repair of damaged nerve fibers
• Anti-inflammation: Reducing neuroinflammatory signaling that amplifies pain
• Neuroprotection: Shielding surviving neurons from further damage

BPC-157 and Nerve Pain Research

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. It has been the subject of numerous animal studies examining its effects on tissue repair and nerve function. In rodent models, BPC-157 has demonstrated:

• Acceleration of peripheral nerve repair after crush injury
• Reduction of pain hypersensitivity behaviors in neuropathic pain models
• Modulation of dopamine and serotonin systems involved in pain processing
• Promotion of angiogenesis (new blood vessel growth) that supports tissue healing

While no published human trials on BPC-157 for PHN exist as of early 2026, the mechanistic overlap between its studied effects and the pathophysiology of PHN makes it a compound of interest to pain researchers.

What the Animal Data Suggests

Studies in rats with sciatic nerve ligation — a standard neuropathic pain model — showed that BPC-157 administration reduced both mechanical allodynia (pain from normally non-painful touch) and thermal hyperalgesia. These are hallmark features of PHN. The proposed mechanism involves upregulation of growth hormone receptor expression and local nitric oxide pathway modulation, which influences vasodilation and nerve healing at the injury site.

Other Peptides in the Nerve Pain Research Space

BPC-157 is not the only peptide studied in the context of neuropathic pain. Researchers have also investigated:

• Cerebrolysin: A neuropeptide mixture studied for neurotrophic activity, with some clinical research in neurological conditions
• LL-37: An antimicrobial peptide with immunomodulatory properties that may affect pain signaling
• Semax: A synthetic ACTH-derived peptide with studied neuroprotective effects in animal models

Current Limitations of the Research

There are several important caveats any researcher must understand before drawing conclusions:

• The majority of studies are conducted in rodents — translation to human physiology is not guaranteed
• PHN involves viral-induced neuronal scarring, which may not be fully replicable in standard nerve-crush models
• Dosing, bioavailability, and delivery methods (subcutaneous, oral, intrathecal) all affect outcomes significantly
• No randomized controlled trials in PHN patients have been completed for any of these peptides

Research Products

For researchers studying peptide compounds in the context of neuropathic pain and nerve repair, NorthPeptide supplies high-purity, third-party-tested research peptides.

Related Research Articles

PubMed Citations